Despite Revvity’s underperformance compared to its industry peers over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Despite Align Technology’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.
West Pharmaceutical Services has underperformed the broader market over the past year, but Wall Street analysts remain optimistic about the stock’s prospects.
Thermo Fisher Scientific has underperformed relative to the broader market over the past year, yet analysts are bullish on the stock's potential.
First Trust Advisors L.P. (“First Trust”), a leading exchange-traded fund (“ETF”) provider and asset manager, announced today that it has launched a new ETF, the First Trust Indxx Medical Devices...